8-K: NEXGEL Reports 121% Revenue Increase in First Quarter 2025, Gross Profit Soars

NEXGEL announces a significant revenue increase of 121% in Q1 2025, driven by growth in both contract manufacturing and branded products, alongside improved gross profit margins.

Summary

• NEXGEL reported its first quarter 2025 financial results, showing substantial revenue growth.
• Net revenue reached $2.81 million, a 121% increase compared to $1.27 million in Q1 2024.
• Gross profit was $1.19 million, significantly higher than the $0.16 million reported in the same period last year.
• Gross profit margin improved to 42.4% from 12.6% in Q1 2024.
• The company's net loss decreased to $0.71 million from $0.85 million year-over-year.
• EBITDA was ($0.54) million, an improvement from ($0.84) million in Q1 2024.
• Adjusted EBITDA was ($0.47) million, compared to ($0.73) million in the prior year's quarter.
• As of March 31, 2025, NEXGEL had a cash balance of $1.19 million.
• The company reaffirmed its 2025 revenue guidance of $13 million and expects to achieve positive EBITDA during the year.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant revenue growth and improved gross margins, but the company is still operating at a loss; the reaffirmed guidance and management's confidence contribute to a moderately positive sentiment.

Positives

• Significant revenue growth of 121% year-over-year in Q1 2025.
• Substantial improvement in gross profit margin to 42.4%.
• Reduction in net loss compared to the same quarter last year.
• Positive outlook with reaffirmed revenue guidance and expectation of achieving positive EBITDA in 2025.

Negatives

• The company still reported a net loss of $0.71 million for Q1 2025.
• EBITDA and Adjusted EBITDA remain negative, although improved compared to the previous year.
• Selling, general and administrative expenses increased to $1.96 million from $1.03 million in Q1 2024.

Risks

• The company's ability to achieve its revenue guidance and positive EBITDA depends on various factors, including contract manufacturing deals and new product launches.
• Increased selling, general, and administrative expenses could impact profitability.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

NEXGEL anticipates generating $13 million in revenue for 2025 and achieving positive EBITDA during the year, driven by contract manufacturing and new product launches.

Management Comments

• Adam Levy, NEXGEL's Chief Executive Officer, stated that revenue for the first quarter came in slightly higher than previously issued guidance.
• Adam Levy commented that gross margins returned to the low to mid-40s, while the EBITDA loss continued to narrow.
• Adam Levy mentioned multiple shots on goal with large existing customers such as Cintas and new potential customers in the contract manufacturing pipeline.
• Adam Levy noted several growth levers in consumer branded products with new product launches throughout the remainder of this year, heading into 2026.

Industry Context

NEXGEL operates in the healthcare and consumer products industry, focusing on hydrogel technology; the company's growth is tied to its ability to secure contract manufacturing deals and successfully launch new branded products.

Comparison to Industry Standards

• Comparing NEXGEL's revenue growth of 121% to competitors in the hydrogel and advanced wound care market, such as Smith & Nephew or Convatec, would require analyzing their respective quarterly reports for similar growth metrics.
• NEXGEL's gross margin of 42.4% can be benchmarked against industry leaders like 3M in their healthcare segment, which typically maintain gross margins in the 50-60% range, indicating room for further improvement.
• The company's focus on contract manufacturing is similar to that of companies like Plexus Corp, which provides manufacturing services across various industries, and their success can be gauged by comparing their contract backlog and revenue conversion rates.
• Comparing NEXGEL's EBITDA and Adjusted EBITDA to similar-sized companies in the medical device or consumer healthcare space would provide insights into its operational efficiency and cost management.

Related Party Transactions

• Accounts payable to related party totaled $499,000 as of March 31, 2025, compared to $531,000 as of December 31, 2024.

Stakeholder Impact

• Shareholders may view the revenue growth and improved gross margins positively.
• Employees could benefit from the company's growth and potential profitability.
• Customers can expect new product launches and continued supply of hydrogel products.
• Suppliers may see increased demand due to higher production volumes.

Next Steps

• The company plans to continue focusing on contract manufacturing opportunities with existing and new customers.
• NEXGEL intends to launch new consumer branded products throughout the remainder of 2025 and into 2026.
• The company will work towards achieving its 2025 revenue target of $13 million and positive EBITDA.

Key Dates

Keywords

NEXGEL, financial results, Q1 2025, revenue, gross profit, EBITDA, hydrogel, contract manufacturing, branded products